Dr. William Bensinger, myeloma expert from the Seattle Cancer Care Alliance, discusses research results that offer hope for patients who experience disease relapse after an allogeneic stem cell transplant.
Dr. William Bensinger shares results from a study reported at ASH 2012 using an older drug, amifostine, in a new way; protecting patients from toxicity while patients receive higher and more effective doses of cancer-fighting drugs.
Dr. Jeff Sharman discusses how treatments such as chemotherapy and FCR will be a thing of the past while targeted therapies continue to advance with the hope of a decrease in toxicty with an increase of efficacy.
New updated research results on Jakafi (ruxolitinib) show positive news to prove to be more effective than hydroxyurea for the treatment of myelofibrosis, according to a new study released at ASH 2012.
Personalized medicine is the future of myeloma treatment. Dr. Shaji Kumar discusses how the variety of therapies and better understanding of genetic components are coming together to achieve better outcomes.
Research is showing that proteasome inhibitors are incredibly effective at treating many stages of myeloma. Dr. Shaji Kumar talks about how this therapy is becoming a new backbone treatment for myeloma.